- Joined
- Jun 19, 2008
- Messages
- 3
- Reaction score
- 2
Hey guys!
If you are looking for an easy way to stay up-to-date in optometry, 20/20 Glance is a great option. It's a once a week email that gives a rundown on clinically relevant optometry news and research for the past week. Here is the most recent one!
(pasted from an email so links aren't working but you get the idea. View the real email here. And signup here.
Weekly Glance for July 3rd
View this email in your browser
What's new in optometry, week by week.
YOUR RUNDOWN
Magnets can reduce nystagmus.
A case study published in Ophthalmology details an innovative surgical procedure to help a patient with acquired nystagmus. The patient was 49-years-old and developed nystagmus secondary to Hodgkin's lymphoma. He underwent a surgery to implant a "magnetic oculomotor prosthesis".
What does that mean?
Two tiny magnets (3mm in size) were placed in the orbit. One was sutured to an EOM, the other to the orbital wall.
And that was done because...
Here is the idea. Although nystagmus originates in the central nervous system for a variety of reasons, the end result involves moving the EOM's. The authors suggest that an intervention that targets the EOM's could offer a more effective treatment for nystagmus, regardless of the cause.
How do the magnets help?
The magnets attract with enough pull to steady the nystagmus but not so much that voluntary eye movements are hindered.
How is the patient doing?
Good. He read one line better on the eye chart and showed dampening of the nystagmus which was sustained through a 4 year follow up.
Who wouldn't be considered a candidate?
Anyone that would need a MRI routinely.
Got a case of unexplained corneal edema? Recheck the med list.
A poster presented at Optometry's Meeting discussed the ocular side effects of amantadine.
What is Amantadine?
It's a medication that is "currently used primarily for Parkinson's disease and other movement disorders, as well as for fatigue associated with multiple sclerosis". The authors detail a case report of a 61-year-old type 2 diabetic with MS. He presented with acute onset bilateral corneal edema and amantadine was determined to be the cause.
How exactly does that happen?
Good question. The mechanism isn't totally understood but prolonged use of amantadine may cause a decrease in endothelial cell count and thus increased corneal edema. (via)
As if the artificial tear aisle wasn't confusing enough...
Allergan introduced a new artificial tear, REFRESH OPTIVE MEGA-3.
It's good for MGD patients because it's "formulated with flaxseed and castor oil, two natural, plant-based oils which protect tears from evaporating". (via)
WHAT YOUR PATIENT MIGHT ASK YOU
Do you prescribe certain medications because of perks the drug companies give you?
Allergan has agreed to pay $13 million to the government and several states for whistleblowing claims made by two ophthalmologists. The OMD's said that Allergan "provided business consulting and services to doctors as a way of encouraging them to prescribe the company's eye care products". (via)
How bad is it if a firecracker explodes in my eye?
Here, let me show you a picture.
SOCIAL MEDIA ROUNDUP
Zeiss is launching a new retinal camera that rivals the Optos and the hype feels a little like when Apple is about to launch a new product. Sneak peak here.
Need some social media help? Two optometry social media queens want to teach you. Sign up for their workshop here.
Ever wonder why Harry Potter didn't have the same eye color in the book as in the movie? Because colored contacts were too uncomfortable. (via)
Check "read optometry news" off your to-do list. And it's a short week! Boom! (Get it? Fourth of July...fireworks pun...OK, it's not as funny if I have to explain it).
See you next week!
Jackie Garlich
Editor & Founder // 20/20 Glance
If you are looking for an easy way to stay up-to-date in optometry, 20/20 Glance is a great option. It's a once a week email that gives a rundown on clinically relevant optometry news and research for the past week. Here is the most recent one!
(pasted from an email so links aren't working but you get the idea. View the real email here. And signup here.
Weekly Glance for July 3rd
View this email in your browser
What's new in optometry, week by week.
YOUR RUNDOWN
Magnets can reduce nystagmus.
A case study published in Ophthalmology details an innovative surgical procedure to help a patient with acquired nystagmus. The patient was 49-years-old and developed nystagmus secondary to Hodgkin's lymphoma. He underwent a surgery to implant a "magnetic oculomotor prosthesis".
What does that mean?
Two tiny magnets (3mm in size) were placed in the orbit. One was sutured to an EOM, the other to the orbital wall.
And that was done because...
Here is the idea. Although nystagmus originates in the central nervous system for a variety of reasons, the end result involves moving the EOM's. The authors suggest that an intervention that targets the EOM's could offer a more effective treatment for nystagmus, regardless of the cause.
How do the magnets help?
The magnets attract with enough pull to steady the nystagmus but not so much that voluntary eye movements are hindered.
How is the patient doing?
Good. He read one line better on the eye chart and showed dampening of the nystagmus which was sustained through a 4 year follow up.
Who wouldn't be considered a candidate?
Anyone that would need a MRI routinely.
Got a case of unexplained corneal edema? Recheck the med list.
A poster presented at Optometry's Meeting discussed the ocular side effects of amantadine.
What is Amantadine?
It's a medication that is "currently used primarily for Parkinson's disease and other movement disorders, as well as for fatigue associated with multiple sclerosis". The authors detail a case report of a 61-year-old type 2 diabetic with MS. He presented with acute onset bilateral corneal edema and amantadine was determined to be the cause.
How exactly does that happen?
Good question. The mechanism isn't totally understood but prolonged use of amantadine may cause a decrease in endothelial cell count and thus increased corneal edema. (via)
As if the artificial tear aisle wasn't confusing enough...
Allergan introduced a new artificial tear, REFRESH OPTIVE MEGA-3.
It's good for MGD patients because it's "formulated with flaxseed and castor oil, two natural, plant-based oils which protect tears from evaporating". (via)
WHAT YOUR PATIENT MIGHT ASK YOU
Do you prescribe certain medications because of perks the drug companies give you?
Allergan has agreed to pay $13 million to the government and several states for whistleblowing claims made by two ophthalmologists. The OMD's said that Allergan "provided business consulting and services to doctors as a way of encouraging them to prescribe the company's eye care products". (via)
How bad is it if a firecracker explodes in my eye?
Here, let me show you a picture.
SOCIAL MEDIA ROUNDUP
Zeiss is launching a new retinal camera that rivals the Optos and the hype feels a little like when Apple is about to launch a new product. Sneak peak here.
Need some social media help? Two optometry social media queens want to teach you. Sign up for their workshop here.
Ever wonder why Harry Potter didn't have the same eye color in the book as in the movie? Because colored contacts were too uncomfortable. (via)
Check "read optometry news" off your to-do list. And it's a short week! Boom! (Get it? Fourth of July...fireworks pun...OK, it's not as funny if I have to explain it).
See you next week!
Jackie Garlich
Editor & Founder // 20/20 Glance
